Is MYOCARDIAL INFARCTION a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed MYOCARDIAL INFARCTION.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 35 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported MYOCARDIAL INFARCTION to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and MYOCARDIAL INFARCTION. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause MYOCARDIAL INFARCTION, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes MYOCARDIAL INFARCTION. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if MYOCARDIAL INFARCTION ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing MYOCARDIAL INFARCTION: 35
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where MYOCARDIAL INFARCTION is a reported side effect: 1.0514%

FDA reports of any drug causing MYOCARDIAL INFARCTION : 106019
Average percentage for all medicated patients where MYOCARDIAL INFARCTION is reported as a complication: 0.6645%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with MYOCARDIAL INFARCTION:

VIOXX (43582 patients)
AVANDIA (20362 patients)
ASPIRIN (9976 patients)
CELEBREX (8297 patients)
LIPITOR (5753 patients)
BEXTRA (5233 patients)
PLAVIX (4945 patients)
AVANDAMET (3119 patients)
ZOCOR (3101 patients)
AVONEX (3096 patients)
LISINOPRIL (3078 patients)
LASIX (2936 patients)
DIANEAL (2589 patients)
TOPROL-XL (2452 patients)
NEXIUM (2353 patients)
ATENOLOL (2220 patients)
SEROQUEL (2125 patients)
NORVASC (2120 patients)
GLUCOPHAGE (2071 patients)
FOSAMAX (2033 patients)
METFORMIN HCL (2005 patients)
FUROSEMIDE (1911 patients)
SIMVASTATIN (1888 patients)
NITROGLYCERIN (1864 patients)
PREDNISONE (1861 patients)
CRESTOR (1833 patients)
INSULIN (1765 patients)
LANTUS (1729 patients)
SYNTHROID (1691 patients)
HYDROCHLOROTHIAZIDE (1661 patients)
COUMADIN (1646 patients)
DIGOXIN (1629 patients)
PRILOSEC (1582 patients)
NEURONTIN (1573 patients)
HEPARIN SODIUM INJECTION (1529 patients)
DIOVAN (1453 patients)
[THERAPY UNSPECIFIED] (1427 patients)
PROTONIX (1415 patients)
FORTEO (1357 patients)
PREVACID (1340 patients)
METOPROLOL TARTRATE (1324 patients)
METOPROLOL (1321 patients)
COREG (1320 patients)
OMEPRAZOLE (1312 patients)
FOLIC ACID (1304 patients)
PREMARIN (1290 patients)
XANAX (1288 patients)
METHOTREXATE (1278 patients)
ALBUTEROL (1255 patients)
LOPRESSOR (1237 patients)
GLYBURIDE (1237 patients)
HUMIRA (1226 patients)
ZOLOFT (1156 patients)
REMICADE (1150 patients)
ALTACE (1114 patients)
TYLENOL (CAPLET) (1109 patients)
ZYPREXA (1089 patients)
VICODIN (1072 patients)
ACTOS (1058 patients)
ALLOPURINOL (1046 patients)
AMBIEN (1041 patients)
IBUPROFEN (1035 patients)
POTASSIUM CHLORIDE (1016 patients)
METFORMIN (1012 patients)
ACETAMINOPHEN (977 patients)
PAXIL (970 patients)
HUMALOG (957 patients)
AMARYL (952 patients)
GLIPIZIDE (895 patients)
COZAAR (883 patients)
ADVAIR DISKUS 100/50 (880 patients)
LEVOTHYROXINE SODIUM (850 patients)
ENBREL (846 patients)
OXYCONTIN (830 patients)
ZETIA (819 patients)
ROSIGLITAZONE MALEATE (813 patients)
PREDNISOLONE (808 patients)
TRASYLOL (802 patients)
HEPARIN (788 patients)
GLUCOTROL (785 patients)
RAMIPRIL (777 patients)
ACETYLSALICYLIC ACID SRT (769 patients)
YASMIN (754 patients)
LORAZEPAM (747 patients)
LYRICA (745 patients)
PERCOCET (735 patients)
PROZAC (731 patients)
PRAVACHOL (724 patients)
WARFARIN SODIUM (712 patients)
ZESTRIL (707 patients)
YAZ (701 patients)
SPIRIVA (698 patients)
DARVOCET (691 patients)
TRICOR (672 patients)
DURAGESIC-100 (669 patients)
IMDUR (667 patients)
BYETTA (666 patients)
PREMPRO (662 patients)
ZANTAC (656 patients)
AVANDARYL (653 patients)
VIAGRA (645 patients)
LEXAPRO (634 patients)
VYTORIN (632 patients)
REVLIMID (630 patients)
ENALAPRIL MALEATE (626 patients)
WELLBUTRIN (624 patients)
LEVAQUIN (617 patients)
ZOMETA (617 patients)
TYLENOL (615 patients)
LORTAB (615 patients)
METOPROLOL SUCCINATE (610 patients)
GABAPENTIN (605 patients)
ALLEGRA (600 patients)
ALPRAZOLAM (598 patients)
SINGULAIR (590 patients)
ATIVAN (589 patients)
CLOPIDOGREL (586 patients)
REBIF (586 patients)
NAPROXEN (574 patients)
ULTRAM (574 patients)
AMLODIPINE (574 patients)
EFFEXOR (562 patients)
CARVEDILOL (562 patients)
ATORVASTATIN CALCIUM (552 patients)
CARDIZEM (550 patients)
PREDNISONE TAB (543 patients)
ACCUPRIL (543 patients)
VALIUM (542 patients)
RANITIDINE (540 patients)
MULTI-VITAMIN (539 patients)
CYMBALTA (539 patients)
DEXAMETHASONE (534 patients)
SPIRONOLACTONE (530 patients)
RISPERDAL (519 patients)
CHANTIX (515 patients)
MORPHINE (513 patients)
CLONIDINE (512 patients)
NIASPAN (504 patients)
CELEXA (503 patients)
LUCENTIS (501 patients)
FLOMAX (497 patients)
HYDROCODONE BITARTRATE (492 patients)
CLOZARIL (487 patients)
VITAMIN D (487 patients)
FLEXERIL (486 patients)
CLONAZEPAM (484 patients)
LOVENOX (479 patients)
ISOSORBIDE MONONITRATE (472 patients)
VITAMIN E (467 patients)
CLOPIDOGREL BISULFATE (461 patients)
ZYRTEC (455 patients)
LANOXIN (453 patients)
HUMULIN R (452 patients)
COMBIVENT (445 patients)
PEPCID (442 patients)
LOTREL (437 patients)
LANSOPRAZOLE (434 patients)
AMOXICILLIN (432 patients)
ASCORBIC ACID (432 patients)
VITAMINS (UNSPECIFIED) (432 patients)
HUMULIN N (424 patients)
ISOSORBIDE (423 patients)
DIAZEPAM (420 patients)
PRINIVIL (410 patients)
ADVIL (410 patients)
CLARITIN (406 patients)
FLONASE (404 patients)
DARVON (401 patients)
ACIPHEX (401 patients)
HEPARIN SODIUM (396 patients)
CALCIUM (396 patients)
VASOTEC (395 patients)
TRAMADOL HCL (393 patients)
PROPOXYPHENE HCL AND ACETAMINOPHEN (392 patients)
CLOZAPINE (392 patients)
ZITHROMAX (390 patients)
NOVOLOG (390 patients)
TENORMIN (385 patients)
LOVASTATIN (376 patients)
TYSABRI (375 patients)
MOTRIN (375 patients)
VERAPAMIL (374 patients)
BISOPROLOL FUMARATE (373 patients)
ALDACTONE (368 patients)
FENTANYL (367 patients)
MULTI-VITAMINS (361 patients)
AVAPRO (358 patients)
HYZAAR (358 patients)
PRAVASTATIN (356 patients)
TRAZODONE HCL (355 patients)
LEVOXYL (351 patients)
TEMAZEPAM (348 patients)
BETASERON (347 patients)
ELAVIL (346 patients)
FLUOROURACIL (345 patients)
AREDIA (345 patients)
METFORMIN HYDROCHLORIDE (344 patients)
KLOR-CON (344 patients)
ZELNORM (342 patients)
OXYCODONE HCL (342 patients)
ATROVENT (338 patients)
ALEVE (336 patients)
REGLAN (334 patients)
AMIODARONE HCL (334 patients)
DARVOCET-N 100 (333 patients)
SOMA (333 patients)
PROPOXYPHENE NAPSYLATE W/ ACETAMINOPHEN (332 patients)
PRADAXA (326 patients)
PROPACET 100 (326 patients)
FISH OIL (325 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about MYOCARDIAL INFARCTION and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.